Evidence map›Paper›PMID 35675841›Full record

ArticleNature medicine2022

Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.

Joseph A Lewnard, Vennis X Hong, Manish M Patel, Rebecca Kahn, Marc Lipsitch, Sara Y Tartof

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05559138 (Analysis of Clinical Characteristics of Hemodialysis Patients With Omicron Infection), which is not on this map. Cited by 250 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
250citing papers in PubMed, 9 pooled it
36.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05559138 completednot on this map

Analysis of Clinical Characteristics of Hemodialysis Patients With Omicron Infection

TypeobservationalSponsorRenJi HospitalRan2022 to 2022Enrolled260ConditionsCOVID-19Armsno intervention
3 · Its place in the literature

Who cites it

250 citing papers in PubMed, 9 syntheses or guidelines pooled it, 362 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  9. Pooled it
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

190 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Joseph A LewnardDivision of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA. jLewnard@berkeley.edu.
Vennis X HongDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Manish M PatelCOVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Rebecca KahnCOVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Marc LipsitchCOVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Sara Y TartofDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. sara.Y.Tartof@kp.org.ORCID http://orcid.org/0000-0003-2336-8476
Centers for Disease Control and Prevention · USKaiser Permanente · USBerkeley College · US

Funding

Emerging methods and applications for test-negative studies of of infectious disease interventionsR01AI148127 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI JEWELL, NICHOLAS P · 2020 to 2023
$1.8M
NIAID NIH HHS R01 AI148127
6 · The paper itself

Abstract

Epidemiologic surveillance has revealed decoupling of Coronavirus Disease 2019 (COVID-19) hospitalizations and deaths from case counts after emergence of the Omicron (B.1.1.529) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant globally. However, assessment of the relative severity of Omicron variant infections presents challenges because of differential acquired immune protection against Omicron and prior variants and because longer-term changes have occurred in testing and healthcare practices. Here we show that Omicron variant infections were associated with substantially reduced risk of progression to severe clinical outcomes relative to time-matched Delta (B.1.617.2) variant infections within a large, integrated healthcare system in Southern California. Adjusted hazard ratios (aHRs) for any hospital admission, symptomatic hospital admission, intensive care unit admission, mechanical ventilation and death comparing individuals with Omicron versus Delta variant infection were 0.59 (95% confidence interval: 0.51-0.69), 0.59 (0.51-0.68), 0.50 (0.29-0.87), 0.36 (0.18-0.72) and 0.21 (0.10-0.44), respectively. This reduced severity could not be explained by differential history of prior infection among individuals with Omicron or Delta variant infection and was starkest among individuals not previously vaccinated against COVID-19 (aHR = 0.40 (0.33-0.49) for any hospital admission and 0.14 (0.07-0.28) for death). Infections with the Omicron BA.2 subvariant were not associated with differential risk of severe outcomes in comparison to BA.1/BA.1.1 subvariant infections. Lower risk of severe clinical outcomes among individuals with Omicron variant infection should inform public health response amid establishment of the Omicron variant as the dominant SARS-CoV-2 lineage globally.

Indexed as

COVID-19SARS-CoV-2CaliforniaHumansPublic Health

Identifiers

PMID35675841
PMCPMC10208005
OpenAlexW4281784908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.